This content is machine translated Urothelial carcinoma Immune and targeted therapy options: Evidence situation 2025/2026 The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data...…
View Post 3 min This content is machine translated Bladder Cancer Effective treatment even in advanced stages Carcinoma of the urinary bladder is one of the common malignant diseases. While the prognosis of patients with superficial tumors is usually favorable, the situation is much worse for muscle-infiltrating…
View Post 10 min This content is machine translated Advanced urothelial carcinoma of the urinary bladder Systemic therapy With approximately 1150 new cases annually in Switzerland, urothelial carcinoma of the urinary bladder is one of the most common cancers of older age. Particularly in the metastatic setting, it… CME-Test
View Post 10 min This content is machine translated Advanced urothelial carcinoma of the urinary bladder Systemic therapy With approximately 1150 new cases annually in Switzerland, urothelial carcinoma of the urinary bladder is one of the most common cancers of older age. Particularly in the metastatic setting, it… CME-Test
View Post 1 min This content is machine translated Advanced bladder cancer Prolonged progression-free survival with combination therapy Preliminary study results suggest that the addition of immunotherapy to conventional chemotherapy may improve progression-free survival in patients with advanced bladder cancer. Is a paradigm shift on the horizon?
